| 841/1507 | US=47 / Câncer Bender RP, Osheroff N. DNA topoisomerases as targets for the chemotherapeutic treatment of cancer. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 57-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. TOPOISOMERASES DE DNA; CANCER. TERAPIA; QUIMIOTERAPIA; TOPOISOMERASE II; TOPOISOMERASE IIALFA; TOPOISOMERASE IIBETA; TOPOISOMERASE II POISONS; FARMACOS ANTICANCERIGENOS; GENOTOXICIDADE; LEUCEMIA; DNA SUPERCOILING; LESAO DNA |
| 842/1507 | US=47 / Câncer Ackermann JM, El-Deiry WS. Targeting ATM/ATR in the DNA damage checkpoint. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 93-116. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO ATM/ATR; DANOS AO DNA; ATAXIA TELANGIECTASIA; RADIACAO IONIZANTE; FOSFORILACAO |
| 843/1507 | US=47 / Câncer Kawabe T. Compounds that abrogate the G2 checkpoint. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 117-33. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CICLO CELULAR; G1; G2; ONCOGENESE; TERAPIA DO CANCER; DANOS AO DNA; REPARO DO DNA; MUTACAO |
| 844/1507 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 845/1507 | US=47 / Câncer Toyota M, Kashima L, Tokino T. CHFR as a potential anticancer target. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 163-76. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CHFR; AGENTE ANTICANCERIGENO; CHECKPOINT MITOTICO; CHECKPOINT PROFASE; TUBULINA; UBIQUITINA LIGASE E3; MITOSE |
| 846/1507 | US=47 / Câncer Villalona-Calero MA, Schaaf L, Turowski R. Antimicrotubule agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 177-205. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. AGENTES ANTIMICROTUBULOS; TUBULINA; ALCALOIDES DA VINCA; TAXANOS; EPOTILONAS; RESISTENCIA TUMOR; ALBUMINA |
| 847/1507 | US=47 / Câncer Sarli V, Giannis A. Kinesin motor inhibitors as effective anticancer drugs. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 207-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES KINESIN; DROGAS ANTICANCER; KINESINAS; ANTIMITOTICOS; EG5 HUMANA |
| 848/1507 | US=47 / Câncer Kang J, Yu H. Targeting the spindle checkpoint in cancer chemotherapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 227-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO DO CHECKPOINT MITOTICO; QUIMIOTERAPIA; MITOSE; SEGREGACAO DOS CROMOSSOMOS; CHECKPOINT MITOTICO; ANEUPLOIDIA; ANAFASE; UBIQUITINACAO; ANTIMITOTICOS; MAD2; CDC20; BUB1 |
| 849/1507 | US=47 / Câncer Shakalya K, Mahadevan D. Antiproliferation inhibitors targeting aurora kinases. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 243-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES ANTI-PROLIFERACAO; AURORA QUINASE; MITOSE; CICLO CELULAR; PROTO-ONCOGENES; INIBIDORES DA PROTEINA-QUINASE; ANEUPLOIDIA; CITOCINESE |
| 850/1507 | US=47 / Câncer Dai W, Yang Y, Jiang N. Plks as novel targets for cancer drug design. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 271-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. PLKS; MEDICAMENTO ANTICANCER; POLO-LIKE QUINASES; PLK1; MITOSE; INIBIDORES; DROGAS ANTI-CANCER; FOSFORILACAO |
| 851/1507 | US=47 / Câncer Gabrielli B, Stevens F, Beamish H. Do histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure?. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 291-309. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DAS HISTONAS DESACETILASES; CONTROLE DO CICLO CELULAR; HETEROCROMATINA; LETALIDADE SINTETICA; PASSAGEIROS CROMOSSOMICOS |
| 852/1507 | US=34 / Imagem Tartar M, Comstock CE, Kipper MS. Radiation therapy effects and considerations. In: ___. Breast cancer imaging: a multidisciplinary, multimodality approach. Philadelphia: Mosby Elsevier, 2008. p. 570-604. ISBN 978-0-323-04677-0. CANCER DE MAMA; RADIOTERAPIA; TERAPIA DE RADIACAO; ESTUDO DE CASO |
| 853/1507 | US=44 / Gastro Wolfsen HC. Esophageal adenocarcinoma: ablation, novel agents, and endoscopic therapy for esophageal dysplasia and carcinoma. In: Jankowski J, Sampliner R, Kerr D, Fong Y. Gastrointestinal oncology: a critical multidisciplinary team approach. Massachuetts: Blackwell Scientific Publications, 2008. p. 87-97. ISBN 978-1-4051-2783-7. ADENOCARCINOMA ESOFAGICO; ABLACAO; TRATAMENTO ENDOSCOPICO; DISPLASIA DO ESOFAGO; CARCINOMA DE ESOFAGO; ADENOCARCINOMA; ESOFAGO DE BARRETT |
| 854/1507 | US=63 / Enfermagem Sorrentino SA. Nutrition support and IV therapy. In: ___. Mosby's textbook for nursing assistants. 7th ed. St. Louis: Elsevier Mosby, 2008. p. 427-38. ISBN 978-0-323-04994-8. SUPORTE NUTRICIONAL; TERAPIA INTRAVENOSA; NUTRICAO ENTERAL; NUTRICAO PARENTERAL |
| 855/1507 | US=64 / Câncer Heffner LT. Staging in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 3-7. (Comtemporary Hematology) ISBN 978-1-934115-82-4. MIELOMA MULTIPLO; TERAPIA-ALVO; MEDICINA TRADUCAO; BIOINFORMATICA; ACIDO TRANS-RETINOICO; GIST; IMATINIB; DASATINIBE; EPIGENETICA; DECITABINA; DETER HIPOTESE CELULAR |
| 856/1507 | US=64 / Câncer Langston AA, Francis D. Epidemiology of multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 9-22. (Comtemporary Hematology) ISBN 978-1-934115-82-4. |
| 857/1507 | US=64 / Câncer Raab MS, Anderson KC. Basic biology of plasma cell dyscrasias: focus on the role of the tumor microenvironment. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 23-39. (Comtemporary Hematology) ISBN 978-1-934115-82-4. BIOLOGIA BASICA DAS CELULAS PLASMATICAS DISCRASIAS; PAPEL DO MICROAMBIENTE TUMORAL |
| 858/1507 | US=64 / Câncer Chng WJ, Bergsagel PL. Biology-based classification and staging of multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 41-56. (Comtemporary Hematology) ISBN 978-1-934115-82-4. BIOLOGIA BASEADA EM MIELOMA MULTIPLO; ESTADIAMENTO DO MIELOMA MULTIPLO |
| 859/1507 | US=64 / Câncer Braggio E, Sebag M, Fonseca R. Cytogenetic abnormalities in multiple myeloma: the importance of FISH and cytogenetics. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 57-76. (Comtemporary Hematology) ISBN 978-1-934115-82-4. |
| 860/1507 | US=64 / Câncer Harousseau JL. Role of autologous stem cell transplantation in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 79-90. (Comtemporary Hematology) ISBN 978-1-934115-82-4. TRANSPLANTE AUTOLOGO DE CELULAS-TRONCO NO MIELOMA MULTIPLO; TERAPIA DE ALTA DOSE; HDT; AUTOLOGO TRANSPLANTE DE CELULAS ESTAMINAIS |